Gastroenterology

Recently the U.S. Food and Drug Administration has recommended the use of Ibsrela (tenapanor), for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. A 50 mg, twice daily oral pill, Ibsrela is a small molecule that acts locally in the gastrointestinal tract to inhibit the sodium-hydrogen exchanger NHE3. The approval came after the positive results based on data from two phases 3, randomized, double-blind, placebo-controlled trials. Irritable Bowel Syndrome (IBS), also known as spastic colon, irritable colon, mucous colitis, and spastic colitis, is a long-term digestive system condition, resulting in cramping, abdominal pain, bloating, ga...